Mitsubishi Tanabe Pharma

  • About Us
    close
    About Us

    Message from
    the Management

    Facts about
    the Company
    • MISSION,VISION 30,Corporate Behavior Charter
    • Materiality
    • Medium-Term
      Management Plan
    • Corporate Profile
    • Management
    • Organization Chart
    • Network
    • Group Companies
    • Brand Mark
    • Corporate History
    • Corporate Original Character
      "Tanamin"
    • Financial Information
    • Compliance
      • Code of Conduct
      • Policies
    • Connecting to Hope
  • News
  • R&D
    close
    R&D

    Pipeline
    • R&D News
    • Definition of precision medicine and social significance
    • Plant-based VLP technology
    • Clinical Trial Information
  • Sustainability
    close
    Sustainability
    Message from the CEO

    Message from the CEO
    Message from the CSO

    Message from the CSO
    • Sustainability News
    • Mitsubishi Tanabe Pharma's Sustainability
    • Materiality
    • Stakeholder Engagement
    • Sustainability Initiatives in the COVID-19 Pandemic

    Sustainability Initiatives

    • Management
    • Environment
    • Society
    • Editorial Policies
    • External Evaluations
    • Data
    • Sustainability Report Archive
    • GRI Standard Comparative Table
    • Explanation of Terms
日本語
Contact Us
Mitsubishi Chemical Holdings Group
Search
menu
Search
  1. HOME
  2. About Us
  3. MISSION,VISION 30,Corporate Behavior Charter

MISSION,VISION 30,Corporate Behavior Charter

中文簡体

MISSION,VISION 30,Corporate Behavior Charter
About Us
  • Message from the Management
  • MISSION,VISION 30,Corporate Behavior Charter
  • Medium-Term Management Plan
  • Corporate Profile
  • Management
  • Organization Chart
  • Network
  • Group Companies
  • Brand Mark
  • Corporate History
  • Facts about the Company
  • Corporate Original Character "Tanamin"
  • Financial Information
  • Compliance
  • Connecting to Hope
  • Download Brochures
News
R&D
  • R&D News
  • Definition of precision medicine and social significance
  • Plant-based VLP technology
  • Pipeline
  • Clinical Trial Information
Sustainability
  • Sustainability News
  • Message from the CEO
  • Message from the CSO
  • Mitsubishi Tanabe Pharma's Sustainability
  • Materiality
  • Stakeholder Engagement
  • Sustainability Initiatives in the COVID-19 Pandemic
  • Management
  • Environment
  • Society
  • Editorial Policies
  • External Evaluations
  • Data
  • Sustainability Report Archive
  • GRI Standard Comparative Table
  • Explanation of Terms
About Us
News
R&D
Sustainability
  • Terms of Use
  • Privacy Policy
  • Site Map
Copyright © Mitsubishi Tanabe Pharma Corporation.
All Rights Reserved.
Page top